Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP and Holzer & Holzer, LLC announce that the United States District Court for the Southern District of California has approved the...
-
NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Greenidge Generation Holdings Inc. (“Greenidge” or the “Company”) (NASDAQ: GREE; GREEL)....
-
NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Electric Last Mile Solutions, Inc. f/k/a Forum Merger III Corporation (“ELMS” or the...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO). Such investors are...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Embark Technology, Inc. (“Embark” or the “Company”) (NASDAQ: EMBK). Such investors are...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rapid Micro Biosystems, Inc. (“Rapid Micro” or the “Company”) (NASDAQ: RPID). Such...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Atea Pharmaceuticals, Inc. (“Atea” or the “Company”) (NASDAQ: AVIR). Such investors are...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA). Such investors are advised to...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ping Identity Holding Corp. (“Ping” or the “Company”) (NYSE: PING). Such investors are...
-
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aligos Therapeutics, Inc. (“Aligos” or the “Company”) (NASDAQ: ALGS). Such investors are...